{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:39:06Z","timestamp":1790714346932,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Modifiable risk factors are hypothesized to account for 30% to 40% of dementia; yet, few trials have demonstrated that risk-reduction interventions, especially multidomain, are efficacious.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine if a personalized, multidomain risk reduction intervention improves cognition and dementia risk profile among older adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Systematic Multi-Domain Alzheimer Risk Reduction Trial was a randomized clinical trial with a 2-year personalized, risk-reduction intervention. A total of 172 adults at elevated risk for dementia (age 70-89 years and with \u22652 of 8 targeted risk factors) were recruited from primary care clinics associated with Kaiser Permanente Washington. Data were collected from August 2018 to August 2022 and analyzed from October 2022 to September 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were randomly assigned to the intervention (personalized risk-reduction goals with health coaching and nurse visits) or to a health education control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was change in a composite modified Neuropsychological Test Battery; preplanned secondary outcomes were change in risk factors and quality of life (QOL). Outcomes were assessed at baseline and 6, 12, 18, and 24 months. Linear mixed models were used to compare, by intention to treat, average treatment effects (ATEs) from baseline over follow-up. The intervention and outcomes were initially in person but then, due to onset of the COVID-19 pandemic, were remote.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. After 2 years, compared with the 90 participants in the control group, the 82 participants assigned to intervention demonstrated larger improvements in the composite cognitive score (ATE of SD, 0.14; 95% CI, 0.03-0.25; <jats:italic>P<\/jats:italic>\u2009=\u2009.02; a 74% improvement compared with the change in the control group), better composite risk factor score (ATE of SD, 0.11; 95% CI, 0.01-0.20; <jats:italic>P<\/jats:italic>\u2009=\u2009.03), and improved QOL (ATE, 0.81 points; 95% CI, \u22120.21 to 1.84; <jats:italic>P<\/jats:italic>\u2009=\u2009.12). There were no between-group differences in serious adverse events (24 in the intervention group and 23 in the control group; <jats:italic>P<\/jats:italic>\u2009=\u2009.59), but the intervention group had greater treatment-related adverse events such as musculoskeletal pain (14 in the intervention group vs 0 in the control group; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial, a 2-year, personalized, multidomain intervention led to modest improvements in cognition, dementia risk factors, and QOL. Modifiable risk-reduction strategies should be considered for older adults at risk for dementia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03683394?term=NCT03683394&amp;amp;amp;rank=1\">NCT03683394<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2023.6279","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T16:45:48Z","timestamp":1701103548000},"page":"54","source":"Crossref","is-referenced-by-count":132,"title":["Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults"],"prefix":"10.1001","volume":"184","author":[{"given":"Kristine","family":"Yaffe","sequence":"first","affiliation":[{"name":"Department of Neurology, University of California, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vittinghoff","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dublin","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie B.","family":"Peltz","sequence":"additional","affiliation":[{"name":"San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Fleckenstein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dori E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Balderson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Larson","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"ioi230078r2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.v18.4","article-title":"2022 Alzheimer\u2019s disease facts and figures.","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"ioi230078r3","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v8.1","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022.","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"ioi230078r4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","article-title":"The Alzheimer\u2019s disease drug development landscape.","volume":"13","author":"van Bokhoven","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"ioi230078r5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi230078r6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"10248","key":"ioi230078r7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"ioi230078r8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence.","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol"},{"issue":"6","key":"ioi230078r9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial.","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"ioi230078r10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jgs.2014.62.issue-1","article-title":"Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.","volume":"62","author":"Rebok","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"ioi230078r12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jama.300.9.1027","article-title":"Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.","volume":"300","author":"Lautenschlager","year":"2008","journal-title":"JAMA"},{"issue":"9984","key":"ioi230078r13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"ioi230078r14","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1111\/jgs.v68.11","article-title":"Lifestyle risk factors and cognitive outcomes from the multidomain dementia risk reduction randomized controlled trial, Body Brain Life for Cognitive Decline (BBL-CD).","volume":"68","author":"McMaster","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"ioi230078r15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol"},{"issue":"10046","key":"ioi230078r16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","article-title":"Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial.","volume":"388","author":"Moll van Charante","year":"2016","journal-title":"Lancet"},{"issue":"s1","key":"ioi230078r17","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.3233\/JAD-180634","article-title":"Systematic Multi-Domain Alzheimer\u2019s Risk Reduction Trial (SMARRT): study protocol.","volume":"70","author":"Yaffe","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"ioi230078r18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1017\/S1041610294001602","article-title":"The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia.","volume":"6","author":"Teng","year":"1994","journal-title":"Int Psychogeriatr"},{"issue":"11","key":"ioi230078r19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"ioi230078r20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"11","key":"ioi230078r21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.2015.63.issue-11","article-title":"American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults.","volume":"63","author":"By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"ioi230078r22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jalz.2012.09.012","article-title":"The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress.","volume":"9","author":"Kivipelto","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"9","key":"ioi230078r23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","article-title":"A neuropsychological test battery for use in Alzheimer disease clinical trials.","volume":"64","author":"Harrison","year":"2007","journal-title":"Arch Neurol"},{"issue":"8","key":"ioi230078r24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/gps.v35.8","article-title":"APPLE-Tree (Active Prevention in People at Risk of Dementia: Lifestyle, Behaviour Change and Technology to Reduce Cognitive and Functional Decline) programme: protocol.","volume":"35","author":"Cooper","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"ioi230078r25","first-page":"A118","article-title":"The Rapid Assessment of Physical Activity (RAPA) among older adults.","volume":"3","author":"Topolski","year":"2006","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"ioi230078r26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"3","key":"ioi230078r27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self-report depression scale for research in the general population.","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"key":"ioi230078r28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jclinepi.2015.08.034","article-title":"The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations.","volume":"73","author":"Hahn","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"ioi230078r29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items.","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"issue":"11","key":"ioi230078r31","article-title":"Multi-domain interventions for the prevention of dementia and cognitive decline.","volume":"11","author":"Hafdi","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ioi230078r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101777","article-title":"Randomised controlled trials for the prevention of cognitive decline or dementia: a systematic review.","volume":"82","author":"Coley","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"1","key":"ioi230078r34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/ADR-200210","article-title":"Engaging patients to design the Systematic Multi-Domain Alzheimer\u2019s Risk Reduction Trial (SMARRT) intervention: findings from a web-based survey.","volume":"4","author":"Marcum","year":"2020","journal-title":"J Alzheimers Dis Rep"},{"issue":"3","key":"ioi230078r35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.14283\/jpad.2022.48","article-title":"The future of AD clinical trials with the advent of anti-amyloid therapies: an CTAD Task Force report.","volume":"9","author":"Delrieu","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"ioi230078r36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease.","volume":"13","author":"Withington","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"ioi230078r37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/jgs.v71.2","article-title":"Impact of COVID-19 policies on perceptions of loneliness in people aged 75?years and over in the cognitive function and aging study (CFAS II).","volume":"71","author":"Richardson","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"ioi230078r38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/gerona\/glac028","article-title":"COVID-19 pandemic impact on trajectories in cardiometabolic health, physical activity, and functioning among adults from the 2006-2020 Health and Retirement Study.","volume":"77","author":"Beydoun","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"ioi230078r39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/geronb\/gbac135","article-title":"Shifting of cognitive assessments between face-to-face and telephone administration: measurement considerations.","volume":"78","author":"Smith","year":"2023","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"ioi230078r11","volume-title":"Preventing Cognitive Decline and Dementia: A Way Forward","author":"Downey","year":"2017"},{"key":"ioi230078r30","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-1353-0","volume-title":"Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models","author":"Vittinghoff","year":"2012","edition":"2nd ed"},{"key":"ioi230078r1","doi-asserted-by":"crossref","unstructured":"Mehegan? L, Rainville? C. 2021 AARP survey on the perceptions related to a dementia diagnosis: adults age 40-plus. AARP. June 22, 2021. Accessed October 20, 2023. https:\/\/www.aarp.org\/content\/dam\/aarp\/research\/surveys_statistics\/health\/2021\/dementia-diagnosis-perceptions.doi.10.26419-2Fres.00471.001.pdf","DOI":"10.26419\/res.00471.006"},{"key":"ioi230078r33","unstructured":"How to sustain brain healthy behaviors: applying lessons of public health and science to drive change. Global Council on Brain Health. 2022. Accessed October 20, 2023. https:\/\/www.aarp.org\/content\/dam\/aarp\/health\/brain_health\/2022-03\/gcbh-behavior-change-report-english.doi.10.26419-2Fpia.00106.001.pdf."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2811803\/jamainternal_yaffe_2023_oi_230078_1703712293.21712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:08:11Z","timestamp":1704211691000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2811803"}},"subtitle":["The SMARRT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2023.6279","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}